Prevalence of latent autoimmune diabetes of adults (LADA) in Southern Spain.

OBJECTIVE To study the prevalence of diabetes mellitus and islet autoantibodies in an adult population from Southern Spain. RESEARCH AND METHODS A cross-sectional study in Southern Spain of 1226 people, age 18-65 years. Clinical data were obtained and a blood sample taken to measure autoantibodies (glutamic acid decarboxylase antibodies (GADAb), tyrosine phosphatase antibodies (IA2Ab), and insulin antibodies (IAA)). An oral glucose tolerance test (OGTT) was also given to 982 of the subjects. RESULTS The overall prevalence of diabetes mellitus according to the WHO 1979 criteria was 10.9% and according to the ADA 1997 criteria it was 14.7% (8.8% were unaware of their diabetes). The prevalence of impaired fasting glucose (IFG) was 12.4% and of impaired glucose tolerance (IGT) 11.5%. The prevalence of GADAb+ in the general population was 0.9% and in the diabetic population 3.7%. There were no significant differences between groups in the prevalence of IA2Ab or IAA (both were 0.8% in the general population). Of the three autoantibodies studied, only GADAb were significantly different in the diabetic population (P=0.0006). CONCLUSIONS The prevalence of Type 2 diabetes and LADA are high in the south of Spain.

[1]  P. Zimmet.  The Pathogenesis and Prevention of Diabetes in Adults: Genes, autoimmunity, and demography , 1995, Diabetes Care.

[2]  R. Tresserras,et al.  Prevalence of diabetes in Catalonia (Spain): an oral glucose tolerance test-based population study. , 1999, Diabetes research and clinical practice.

[3]  A. Karter,et al.  Self-monitoring of blood glucose: language and financial barriers in a managed care population with diabetes. , 2000, Diabetes care.

[4]  Å. Lernmark,et al.  Towards a World Health Organisation (WHO) approved standard sample for islet cell antibodies, GAD65 and IA-2 autoantibodies , 1999, Diabetologia.

[5]  M. Rowley,et al.  Lack of antibodies to glutamic acid decarboxylase in young adults of the high diabetes prevalence Wanigela people of Papua New Guinea. , 1994, Diabetes research and clinical practice.

[6]  W. Irvine,et al.  CLINICAL AND PATHOGENIC SIGNIFICANCE OF PANCREATIC-ISLET-CELL ANTIBODIES IN DIABETICS TREATED WITH ORAL HYPOGLYCÆMIC AGENTS , 1977, The Lancet.

[7]  T. Orchard.  From Diagnosis and Classification to Complications and Therapy: DCCT Part II? , 1994, Diabetes Care.

[8]  L. Groop,et al.  Islet Cell Antibodies Identify Latent Type I Diabetes in Patients Aged 35–75 Years at Diagnosis , 1986, Diabetes.

[9]  Rafael Lozano,et al.  AGE STANDARDIZATION OF RATES: A NEW WHO STANDARD , 2000 .

[10]  C. Perronne,et al.  Pentamidine-Induced Derangements of Glucose Homeostasis: Determinant roles of renal failure and drug accumulation: A study of 128 patients , 1995, Diabetes Care.

[11]  G. Eisenbarth,et al.  Competitive Insulin Autoantibody Assay: Prospective Evaluation of Subjects at High Risk for Development of Type I Diabetes Mellitus , 1987, Diabetes.

[12]  R. Holman,et al.  UKPDS 25: autoantibodies to islet-cell cytoplasm and glutamic acid decarboxylase for prediction of insulin requirement in type 2 diabetes , 1997, The Lancet.

[13]  J. Salvador-Oliván,et al.  Prevalence of Diabetes and Impaired Glucose Tolerance in Aragón, Spain , 1997, Diabetes Care.

[14]  S. Nagataki,et al.  Antibodies to GAD in Japanese diabetic patients: a multicenter study. , 1995, Diabetes research and clinical practice.

[15]  P. Raskin,et al.  Report of the expert committee on the diagnosis and classification of diabetes mellitus. , 1999, Diabetes care.

[16]  R. Hanson,et al.  Diagnosing diabetes mellitus – do we need new criteria? , 1997, Diabetologia.

[17]  J. Stengård,et al.  Antibodies to glutamic acid decarboxylase as predictors of insulin-dependent diabetes mellitus before clinical onset of disease , 1994, The Lancet.

[18]  L. Groop,et al.  Clinical and genetic characteristics of type 2 diabetes with and without GAD antibodies. , 1999, Diabetes.

[19]  P. Latorre,et al.  [Prevalence of non-insulin dependent diabetes mellitus in Lejona (Vizcaya, Spain)]. , 1993, Medicina clinica.

[20]  Å. Lernmark,et al.  β-Cell Function in Relation to Islet Cell Antibodies During the First 3 Yr After Clinical Diagnosis of Diabetes in Type II Diabetic Patients , 1993, Diabetes Care.

[21]  L. Bouter,et al.  Low Prevalence of Antibodies to GAD65 in a 50- to 74-Year-Old General Dutch Population: The Hoorn Study , 1997, Diabetes Care.

[22]  M. Harris,et al.  Undiagnosed NIDDM: Clinical and Public Health Issues , 1993, Diabetes Care.

[23]  M. Farrer,et al.  Assessing the Impact of Blood Sample Type on the Estimated Prevalence of Impaired Glucose Tolerance and Diabetes Mellitus in Epidemiological Surveys , 1995, Diabetic medicine : a journal of the British Diabetic Association.

[24]  R. Hernandez-mejia,et al.  Epidemiology of diabetes mellitus in the province of Leon , 1992 .

[25]  G. Eisenbarth,et al.  Protein Tyrosine Phosphatase-Like Proteins: Link With IDDM , 1997, Diabetes Care.

[26]  E. Bonifacio,et al.  Low prevalence of islet autoimmunity in adult diabetes and low predictive value of islet autoantibodies in the general adult population of northern Italy , 1999, Diabetologia.

[27]  L. Groop,et al.  GAD Antibodies in NIDDM: Ten-year follow-up from the diagnosis , 1995, Diabetes Care.

[28]  M. Rowley,et al.  Antibodies to Glutamic Acid Decarboxylase Discriminate Major Types of Diabetes Mellitus , 1992, Diabetes.

[29]  J. Diamond.  Diabetes running wild , 1992, Nature.

[30]  C. Manes,et al.  Epidemiology of Diabetes Mellitus in the Elderly in Northern Greece: a Population Study , 1995, Diabetic medicine : a journal of the British Diabetic Association.

[31]  O. Rolandsson,et al.  Glutamate decarboxylase (GAD65) and tyrosine phosphatase-like protein (IA-2) autoantibodies index in a regional population is related to glucose intolerance and body mass index , 1999, Diabetologia.

[32]  A. Castro‐Beiras,et al.  Prevalence of diabetes mellitus in the population aged 40-69 years in Galicia, northwest Spain. , 1995, Diabetes research and clinical practice.

[33]  M. Rowley,et al.  The ethnic distribution of antibodies to glutamic acid decarboxylase: presence and levels of insulin-dependent diabetes mellitus in Europid and Asian subjects. , 1993, Journal of diabetes and its complications.

[34]  E. Bonifacio,et al.  Disease Sensitivity and Specificity of 52 Assays for Glutamic Acid Decarboxylase Antibodies: The Second International GADAB Workshop , 1995, Diabetes.

[35]  G. W. Snedecor.  STATISTICAL METHODS , 1967 .

[36]  J. Petersen,et al.  Detection of GAD65 Antibodies in Diabetes and Other Autoimmune Diseases Using a Simple Radioligand Assay , 1994, Diabetes.